

Bridgewest acquires Pfizer manufacturing facility in Australia

03 September 2020 | News

Bridgewest to develop the site into a full-service Contract Development and Manufacturing Organization



The Bridgewest Group, a premier private investment company that focuses on disrupting industries through innovation announced its subsidiary's purchase of Pfizer's biologics manufacturing facility in Adelaide, Australia.

Hospira Adelaide Pty Ltd., an affiliate of Pfizer Inc., will continue to operate the facility under a leaseback arrangement from Bridgewest Australia Real Estate Pty Ltd. until Q3 of 2021, at which time Bridgewest will assume full operational responsibility for the facility and colleagues. Financial terms were not disclosed.

The Adelaide facility has the manufacturing capability, staff expertise, and supporting systems to execute cGMP grade manufacturing and testing of microbial-based products, including proteins, vaccines, and plasmids from development stage through to commercialization.

The facility has experience as a multi-product CDMO (Contract Development and Manufacturing Organization) which moving forward, under Bridgewest's ownership, will be further developed and expanded upon.

Bridgewest intends to invest in operational expansion, including adding capabilities around Mammalian Cell production, Cell and Gene Therapy as well as expanding current capabilities for Microbial and Vaccine production.